Biosimilars Establishing a strong presence in biosimilars is the next frontier for Indian life sciences companies. With biosimilars expected to generate major traction in global markets over the next decade, growing from $12 billion in 2020 to at least $36 billion by 2025 at a CAGR of 24%, studies indicate India does have the potential to supply $5 billion worth of biosimilars globally in the next decade if it overcomes some challenges, reports The Pharma Letter’s India correspondent. 28 September 2021